Digital health is rapidly reshaping how healthcare is delivered, expanding access while introducing new clinical, regulatory, and liability risks. Technologies such as digital therapeutics (DTx) and telehealth platforms are at the forefront of this transformation, enabling more personalized, scalable, and data-driven care models.

At the same time, these innovations place increasing responsibility on companies operating in the space. As more of the patient experience moves to digital platforms, maintaining trust becomes central to how these technologies are adopted and scaled.

This year, as the nation celebrates the 250th anniversary of the American Revolution, the U.S. Food and Drug Administration (“FDA”) is engaged in a revolution of its own: a broad-based effort to forge an alternative pathway for new medical products to reach the public in an expedited fashion.

Spanish explorer Ponce de Leon’s “fountain of youth” is legendary. In St. Augustine, Florida, visitors still flock to a tourist attraction named for that mystical spring, hoping that a drink from the city’s natural waters might turn back their biological clocks.

At least the only consequence of indulging in the Ponce de Leon fantasy is a mouthful of sulfur‑smelling water. Today’s pursuit of the “fountain of youth” carries greater risk. Increasing numbers of consumers are injecting themselves with unapproved peptides based on unsubstantiated claims that these compounds bestow regenerative properties. Many of these products are purchased from online sellers operating outside traditional regulatory oversight, where they have not been tested for either efficacy or safety.